|
|
Vaccine Detail
|
p53 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: p53 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007030
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53 (NCIT_C1986)
- human TP53 (P53)
gene engineering:
- Preparation: Monocyte-derived DC were loaded with two modified HLA-class I p53 peptides (Schuler et al., 2014).
- Description: This is for Breast Cancer and Ovarian Cancer(NCT00001827). A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide vaccine may elicit an HLA-A2.1-restricted cytotoxic T lymphocyte immune response against tumor cells that overexpress p53 protein. (NCI04) (Schuler et al., 2014; NCIT_C1986).
|
| Host Response |
|
|
| References |
NCIT_C1986: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1986]
NCT00001827: p53 Vaccine for Ovarian Cancer [https://clinicaltrials.gov/ct2/show/NCT00001827]
Schuler et al., 2014: Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20(9); 2433-2444. [PubMed: 24583792].
|
|
